secwatch.observer — SEC 8-K summary
======================================

Issuer:     Estrella Immunopharma, Inc. (ESLA)
CIK:        0001844417
Form:       8-K
Filed at:   2024-07-02T23:59:59+00:00
Accession:  0001213900-24-058085
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Estrella Immunopharma merges wholly-owned sub Estrella Biopharma into parent
----------------------------------------------------------------------------

- Merger effective June 30, 2024; Estrella Biopharma ceased to exist, Estrella Immunopharma survives.
- No changes to management, board, ownership, charter, or bylaws as a result of the merger.
- Merger approved by unanimous written consent of board; intended to simplify corporate structure and streamline financial reporting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1844417/000121390024058085/0001213900-24-058085-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1844417/000121390024058085/ea0208757-8k_estrella.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-058085

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer